FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to immunology, and concerns P-selectin glycoprotein ligand 1 modulators. Substance of the invention involves a multimeric compound which is bound with at least two (PSGL-1) proteins on a T-cell surface; said multimeric compound contains two polypeptide chains each of which contains a binding domain which is bound with PSGL-1 and which contains a P-selectin extracellular domain or its binding fragment, or E-selectin extracellular domain or its binding fragment, and also a heterologous amino acid sequence; two polypeptide chains are combined by the heterologous amino acid sequence to produce the multimeric compound.
EFFECT: advantage of the invention consists in the development of the agent to be used to induce T-cell depletion and/or apoptosis.
30 cl, 14 ex, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES | 2005 |
|
RU2482131C2 |
| RECEPTOR FOR VISTA | 2019 |
|
RU2812846C2 |
| P-SELECTIN ANTIBODIES AND METHODS FOR THEIR USING AND IDENTIFICATION | 2011 |
|
RU2603097C2 |
| ANTI-PSGL-1-ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2650817C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS | 2011 |
|
RU2628699C2 |
| TRIFUNCTIONAL ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2753882C2 |
| ANTIBODIES AGAINST CCR7 RECEPTOR FOR CANCER TREATMENT | 2006 |
|
RU2404808C2 |
| EXPRESSION OF NEW CELL MARKS | 2018 |
|
RU2796334C2 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
